Loading...
Please wait, while we are loading the content...
CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity
| Content Provider | Semantic Scholar |
|---|---|
| Author | Parsons, Chris G. |
| Copyright Year | 2019 |
| Abstract | ABSTRACT Drug repurposing is recently gaining increasing attention, not just from pharmaceutical companies but also from government agencies in an attempt to generate new medications to address increasing unmet medical needs in a cost effective and expedite manner. There are several approaches to identify novel indications for known drugs. Many are based on rational selection e.g. the known or a new mechanism of action of a drug. This review will focus rather on phenotypic or high content screening of compounds in models that are believed to be predictive of effectiveness of compounds irrespective of their mechanism of action. Three short cases studies of screens for Alzheimer's disease, Parkinson's disease and spasticity will be given as examples. This article is part of the Special Issue entitled ‘Drug Repurposing: old molecules, new ways to fast track drug discovery and development for CNS disorders’. HighlightsDrug repurposing seems to be “en vogue”.It is a promising approach to find new, efficacious but cost effective and safe drugs to treat high unmet medical needs.This approach has already been taken up by various pharmaceutical companies.There might be even more future interest from the side of the funding/health organizations such as the NHS and NIH.This review is intended as an introduction to papers on more specific aspects published in this issue of Neuropharmacology.The more specific focus is on repurposing based on phenotypic screening rather than rational MoA based approaches. |
| Starting Page | 4 |
| Ending Page | 10 |
| Page Count | 7 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/j.neuropharm.2018.08.027 |
| PubMed reference number | 30165077 |
| Journal | Medline |
| Volume Number | 147 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S0028390818305641 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S0028390818305641?dgcid=api_sd_search-api-endpoint |
| Alternate Webpage(s) | https://doi.org/10.1016/j.neuropharm.2018.08.027 |
| Journal | Neuropharmacology |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
